Literature DB >> 12923914

New TNM staging criteria for head and neck tumors.

Brian O'Sullivan1, Jatin Shah.   

Abstract

Cancers of the head and neck have always represented a unique perspective in cancer staging. Not only are these lesions numerous in terms of anatomic sites of origin, but, unlike most other major cancers, they frequently and readily lend themselves to adequate clinical assessment by visual inspection and palpation, which greatly facilitates documentation by the trained clinician. In addition, their location often involves treatment programs that focus on nonsurgical organ-preservation strategies, and thus anatomic and histological data for comprehensive pathologic staging are often not available. Nevertheless, the processes involved in surgical decision-making and radiotherapy treatment planning require meticulous assessment and documentation of the extent of locoregional disease. For all these reasons it is especially important to perform reliable and accurate pretreatment clinical staging of head and neck cancers. Also, many patients who succumb to head and neck cancer do so as a result of locoregional disease. Therefore, the staging system must take into account detailed local anatomic features that dictate management, since the degree of involvement of these structures by tumor may be as important as distant metastasis in threatening survival. For this reason the most recent cancer staging classification (6th edition) of the International Union Against Cancer (UICC) and the American Joint Committee on Cancer (AJCC) includes new criteria for the more advanced cases (e.g., T4 categories and stage IV disease). These criteria reflect the fact that in heterogeneous populations there is a realistic opportunity for cure in some patients but not in others. This review summarizes the criteria used in the new TNM for head and neck tumors, and outlines the rationale behind the current changes. It also provides some guidance regarding optimal source data to facilitate classification in the registry setting. In addition, the need for additional changes in the future is recognized. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2003        PMID: 12923914     DOI: 10.1002/ssu.10019

Source DB:  PubMed          Journal:  Semin Surg Oncol        ISSN: 1098-2388


  36 in total

1.  Zone-size nonuniformity of 18F-FDG PET regional textural features predicts survival in patients with oropharyngeal cancer.

Authors:  Nai-Ming Cheng; Yu-Hua Dean Fang; Li-yu Lee; Joseph Tung-Chieh Chang; Din-Li Tsan; Shu-Hang Ng; Hung-Ming Wang; Chun-Ta Liao; Lan-Yan Yang; Ching-Han Hsu; Tzu-Chen Yen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-10-23       Impact factor: 9.236

2.  Increased HIF-1alpha expression in tumor cells and lymphocytes of tumor microenvironments predicts unfavorable survival in esophageal squamous cell carcinoma patients.

Authors:  Lin Zhang; Shu-Biao Ye; Ze-Lei Li; Gang Ma; Shi-Ping Chen; Jia He; Wan-Li Liu; Dan Xie; Yi-Xin Zeng; Jiang Li
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

3.  Cooverexpression of ERBB1 and ERBB4 receptors predicts poor clinical outcome in pN+ oral squamous cell carcinoma with extranodal spread.

Authors:  Sabrina Daniela Silva; Moulay A Alaoui-Jamali; Michael Hier; Fernando Augusto Soares; Edgard Graner; Luiz Paulo Kowalski
Journal:  Clin Exp Metastasis       Date:  2013-12-15       Impact factor: 5.150

4.  Impact of podoplanin expression in oral squamous cell carcinoma: clinical and histopathologic correlations.

Authors:  Matthias Kreppel; Martin Scheer; Uta Drebber; Lutz Ritter; Joachim E Zöller
Journal:  Virchows Arch       Date:  2010-05       Impact factor: 4.064

5.  MMP7 is a target of the tumour-associated antigen EpCAM.

Authors:  Sabine Denzel; Brigitte Mack; Carola Eggert; Petra Massoner; Nikolas Stöcklein; Dirk Kemming; Ulrich Harréus; Olivier Gires
Journal:  Int J Exp Pathol       Date:  2012-10       Impact factor: 1.925

6.  Expression levels of B7-H3 and TLT-2 in human oral squamous cell carcinoma.

Authors:  Shan-Shan Zhang; Jing Tang; Shu-Yi Yu; L I Ma; Feng Wang; Shu-LE Xie; Long Jin; Hong-Yu Yang
Journal:  Oncol Lett       Date:  2015-05-27       Impact factor: 2.967

7.  Epithelial-mesenchymal transition (EMT) markers have prognostic impact in multiple primary oral squamous cell carcinoma.

Authors:  Sabrina Daniela da Silva; Grégoire B Morand; Faisal A Alobaid; Michael P Hier; Alex M Mlynarek; Moulay A Alaoui-Jamali; Luiz Paulo Kowalski
Journal:  Clin Exp Metastasis       Date:  2014-11-30       Impact factor: 5.150

8.  Cisplatin and temozolomide combination in the treatment of leptomeningeal carcinomatosis from ethmoid sinus intestinal-type adenocarcinoma.

Authors:  Giuseppe Lombardi; Fable Zustovich; Alessandro Della Puppa; Lucia Borgato; Enrico Orvieto; Renzo Manara; Diego Cecchin; Franco Berti; Patrizia Farina; Marina Paolo Gardiman; Renato Scienza; Vittorina Zagonel
Journal:  J Neurooncol       Date:  2010-12-08       Impact factor: 4.130

9.  The expression profile of Oct4 and Sox2 in the carcinogenesis of oral mucosa.

Authors:  Bin Qiao; Baoxia He; Jinghua Cai; Wenli Yang
Journal:  Int J Clin Exp Pathol       Date:  2013-12-15

10.  Upregulation of CENP-H in tongue cancer correlates with poor prognosis and progression.

Authors:  Wen-Ting Liao; Chun-Ping Yu; Dong-Hui Wu; Ling Zhang; Li-Hua Xu; Gui-Xiang Weng; Mu-Sheng Zeng; Li-Bing Song; Jin-Song Li
Journal:  J Exp Clin Cancer Res       Date:  2009-06-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.